Drug intelligence / Profile preview

BAH249

Development stage: Unknown
Lead developer: Essen Biotech
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BAH249 is an autologous tumor-infiltrating lymphocyte (TIL) therapy being developed by Essen Biotech for the treatment of advanced or metastatic refractory breast cancer. The therapy involves the isolation of T cells, specifically the CD8+ and CD4+ subsets, from a patient's own tumor tissue. These cells are then expanded ex vivo to large numbers and re-infused into the patient. The expanded TILs are designed to recognize and eliminate breast cancer cells by targeting a broad range of tumor-associated antigens. BAH249 is currently in Phase 2 clinical development, focusing on patients who have failed standard-of-care treatments.

Other names: TIL therapyautologous TILsEssen Biotech TILs

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on BAH249.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAH249.

Explore the full profile